疏血通注射液联合前列地尔治疗急性脑梗死的临床观察

发布时间：2018-04-26 05:27

本文选题：疏血通注射液 + 前列地尔注射液　；参考：《中国药房》2017年20期

【摘要】：目的:观察疏血通注射液联合前列地尔治疗急性脑梗死(ACI)的临床疗效及安全性。方法:选取2014年3月-2016年9月我院收治的ACI患者123例作为研究对象,按照随机数字表法分为观察组(62例)和对照组(61例)。对照组患者在常规治疗基础上给予前列地尔注射液2 m L+0.9%氯化钠注射液100 m L,ivgtt,qd;观察组患者在对照组基础上给予疏血通注射液6 m L+0.9%氯化钠注射液250 m L,ivgtt,qd。两组疗程均为2周。比较两组患者治疗前后的血小板平均体积(MPV)、纤维蛋白原(FIB)含量、血液流变学指标、神经功能缺损程度评分,以及临床疗效和不良反应发生情况。结果:治疗前,两组患者的MPV和FIB含量、血液流变学指标及神经功能缺损程度评分比较,差异均无统计学意义(P0.05);与治疗前比较,治疗后两组患者的MPV显著减小,FIB含量、血液流变学指标及改良Rankin量表(m RS)评分均显著降低,巴塞尔指数(BI)和美国国立卫生研究院卒中量表(NIHSS)评分均显著升高,且观察组的各项结果均优于对照组,差异均有统计学意义(P0.05)。观察组患者的总有效率为95.16%,显著高于对照组的85.25%,差异有统计学意义(P0.05)。两组患者均未见严重不良反应发生。结论:疏血通注射液联合前列地尔可显著改善ACI患者神经功能缺损程度,并通过降低MPV和FIB含量来改善患者血液高凝状态,疗效较好,且安全性高。
[Abstract]:Objective: to observe the efficacy and safety of Shuxuetong injection combined with alprostadil in the treatment of acute cerebral infarction (ACI). Methods: 123 patients with ACI admitted in our hospital from March 2014 to September 2016 were randomly divided into observation group (n = 62) and control group (n = 61). The patients in the control group were given alprostadil injection 2 mL 0.9% sodium chloride injection 100 mL iv Gttt QD on the basis of routine treatment, and the observation group patients were given Shuxuetong injection 6 mL 0.9% sodium chloride injection 250 mL iv gttt QD on the basis of the control group. The course of treatment was 2 weeks in both groups. The mean platelet volume (MPV), fibrinogen (FB) content, hemorheology index, neurological deficit score, clinical efficacy and adverse reactions were compared between the two groups before and after treatment. Results: before treatment, there was no significant difference in MPV and FIB content, hemorheology index and neurological impairment score between the two groups, and the MPV content in the two groups was significantly decreased after treatment compared with that before treatment. The hemorheological indexes and modified Rankin scale scores were significantly decreased, and the scores of the Basel index and the National Institutes of Health Stroke scale (NIHSS) were significantly increased, and the results of the observation group were better than those of the control group. The difference was statistically significant (P 0.05). The total effective rate of the patients in the observation group was 95.16, which was significantly higher than that in the control group (85.25%), and the difference was statistically significant (P 0.05). No serious adverse reactions occurred in both groups. Conclusion: Shuxuetong injection combined with alprostadil can significantly improve the degree of nerve function defect in patients with ACI and improve the blood hypercoagulability by reducing the contents of MPV and FIB.
【作者单位】：武汉市新洲区人民医院神经内科;
【分类号】：R743.3

【相似文献】